Ozdemir, Y. Et Al. 2022. In Silico Analysis of a De Novo OTC Variant as a Cause of Ornithine Transcarbamylase Deficiency. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY , vol.30, no.2 , 153-156.

Ozdemir, Y., Cag, M., Gul, Ş., Yuksel, Z., & Ergoren, M. C., (2022). In Silico Analysis of a De Novo OTC Variant as a Cause of Ornithine Transcarbamylase Deficiency. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY , vol.30, no.2, 153-156.

Ozdemir, Yesim Et Al. "In Silico Analysis of a De Novo OTC Variant as a Cause of Ornithine Transcarbamylase Deficiency," APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY , vol.30, no.2, 153-156, 2022

Ozdemir, Yesim Et Al. "In Silico Analysis of a De Novo OTC Variant as a Cause of Ornithine Transcarbamylase Deficiency." APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY , vol.30, no.2, pp.153-156, 2022

Ozdemir, Y. Et Al. (2022) . "In Silico Analysis of a De Novo OTC Variant as a Cause of Ornithine Transcarbamylase Deficiency." APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY , vol.30, no.2, pp.153-156.

@article{article, author={Yesim Ozdemir Et Al. }, title={In Silico Analysis of a De Novo OTC Variant as a Cause of Ornithine Transcarbamylase Deficiency}, journal={APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY}, year=2022, pages={153-156} }